End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-28 pm EDT
|
5-day change
|
1st Jan Change
|
19.95
CNY
|
+4.12%
|
|
+9.80%
|
-31.16%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39,247
|
94,292
|
106,395
|
76,952
|
47,371
|
32,429
|
-
|
-
|
Enterprise Value (EV)
1 |
35,694
|
92,214
|
107,852
|
80,810
|
51,092
|
35,563
|
34,774
|
34,094
|
P/E ratio
|
62.2
x
|
81.5
x
|
68.8
x
|
58.6
x
|
32.1
x
|
21.3
x
|
16.5
x
|
15.9
x
|
Yield
|
0.29%
|
0.25%
|
0.32%
|
0.44%
|
0.69%
|
1.17%
|
1.44%
|
1.2%
|
Capitalization / Revenue
|
10.4
x
|
18.4
x
|
14.3
x
|
7.5
x
|
4.11
x
|
2.57
x
|
2.13
x
|
1.99
x
|
EV / Revenue
|
9.5
x
|
18
x
|
14.5
x
|
7.87
x
|
4.43
x
|
2.81
x
|
2.28
x
|
2.09
x
|
EV / EBITDA
|
37.5
x
|
54.5
x
|
45
x
|
34.8
x
|
18.7
x
|
11.6
x
|
9.05
x
|
8.53
x
|
EV / FCF
|
190
x
|
274
x
|
-3,252
x
|
-101
x
|
-493
x
|
-374
x
|
21
x
|
13.8
x
|
FCF Yield
|
0.53%
|
0.36%
|
-0.03%
|
-0.99%
|
-0.2%
|
-0.27%
|
4.75%
|
7.24%
|
Price to Book
|
5.27
x
|
10.8
x
|
11.1
x
|
7.83
x
|
4.12
x
|
2.56
x
|
2.26
x
|
1.99
x
|
Nbr of stocks (in thousands)
|
1,787,372
|
1,787,372
|
1,786,898
|
1,786,601
|
1,786,732
|
1,787,394
|
-
|
-
|
Reference price
2 |
22.91
|
53.51
|
62.79
|
45.33
|
28.98
|
19.95
|
19.95
|
19.95
|
Announcement Date
|
2/28/20
|
3/28/21
|
3/10/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3,757
|
5,134
|
7,444
|
10,266
|
11,538
|
12,636
|
15,257
|
16,309
|
EBITDA
1 |
951.3
|
1,692
|
2,399
|
2,321
|
2,730
|
3,059
|
3,841
|
3,996
|
EBIT
1 |
652.2
|
874.8
|
1,914
|
1,690
|
1,722
|
1,937
|
2,529
|
2,644
|
Operating Margin
|
17.36%
|
17.04%
|
25.72%
|
16.46%
|
14.92%
|
15.33%
|
16.58%
|
16.22%
|
Earnings before Tax (EBT)
1 |
632.6
|
1,319
|
1,911
|
1,666
|
1,838
|
1,843
|
2,529
|
2,604
|
Net income
1 |
547.2
|
1,172
|
1,661
|
1,375
|
1,601
|
1,605
|
2,176
|
2,255
|
Net margin
|
14.56%
|
22.84%
|
22.31%
|
13.39%
|
13.88%
|
12.7%
|
14.27%
|
13.83%
|
EPS
2 |
0.3681
|
0.6569
|
0.9128
|
0.7739
|
0.9019
|
0.9376
|
1.208
|
1.257
|
Free Cash Flow
1 |
187.4
|
336
|
-33.17
|
-803.9
|
-103.7
|
-95
|
1,653
|
2,468
|
FCF margin
|
4.99%
|
6.54%
|
-0.45%
|
-7.83%
|
-0.9%
|
-0.75%
|
10.84%
|
15.13%
|
FCF Conversion (EBITDA)
|
19.7%
|
19.86%
|
-
|
-
|
-
|
-
|
43.04%
|
61.76%
|
FCF Conversion (Net income)
|
34.25%
|
28.66%
|
-
|
-
|
-
|
-
|
75.97%
|
109.44%
|
Dividend per Share
2 |
0.0667
|
0.1333
|
0.2000
|
0.2000
|
0.2000
|
0.2327
|
0.2876
|
0.2402
|
Announcement Date
|
2/28/20
|
3/28/21
|
3/10/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q4
|
2021 S2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2,121
|
2,193
|
2,940
|
3,286
|
2,142
|
4,158
|
4,635
|
-
|
2,863
|
5,632
|
2,724
|
2,916
|
5,640
|
2,920
|
2,978
|
5,898
|
2,671
|
3,196
|
5,761
|
3,316
|
3,534
|
6,820
|
3,239
|
3,379
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
677.9
|
708.3
|
1,245
|
760.3
|
510.1
|
414.9
|
925
|
431.6
|
482.3
|
913.9
|
414.6
|
424.2
|
838.8
|
268.4
|
466
|
775
|
520.1
|
579.4
|
1,092
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
20.63%
|
33.06%
|
29.93%
|
16.4%
|
-
|
14.49%
|
16.42%
|
15.84%
|
16.54%
|
16.2%
|
14.2%
|
14.25%
|
14.22%
|
10.05%
|
14.58%
|
13.45%
|
15.68%
|
16.39%
|
16.01%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
708.4
|
1,245
|
-
|
464.8
|
458.9
|
-
|
426.6
|
481.9
|
908.5
|
412.4
|
516.9
|
929.4
|
-
|
497
|
765
|
485
|
613
|
1,098
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
564.8
|
621
|
1,096
|
-
|
375.7
|
413.5
|
-
|
348.3
|
437.8
|
786.1
|
352.9
|
462.1
|
815
|
-
|
420
|
635
|
415
|
553
|
968
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
17.19%
|
28.99%
|
26.36%
|
-
|
-
|
14.44%
|
-
|
12.78%
|
15.01%
|
13.94%
|
12.09%
|
15.52%
|
13.82%
|
-
|
13.14%
|
11.02%
|
12.51%
|
15.65%
|
14.19%
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.2000
|
0.2598
|
-
|
-
|
-
|
-
|
-
|
0.2300
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
8/26/20
|
3/28/21
|
8/29/21
|
3/10/22
|
3/10/22
|
8/29/22
|
10/27/22
|
3/30/23
|
3/30/23
|
4/27/23
|
8/27/23
|
8/27/23
|
10/29/23
|
3/27/24
|
3/27/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
1,457
|
3,859
|
3,721
|
3,133
|
2,345
|
1,665
|
Net Cash position
1 |
3,553
|
2,077
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.6074
x
|
1.663
x
|
1.363
x
|
1.024
x
|
0.6104
x
|
0.4166
x
|
Free Cash Flow
1 |
187
|
336
|
-33.2
|
-804
|
-104
|
-95
|
1,653
|
2,468
|
ROE (net income / shareholders' equity)
|
10.9%
|
14.1%
|
17.3%
|
13.3%
|
13.9%
|
12.2%
|
13.9%
|
12.9%
|
ROA (Net income/ Total Assets)
|
7.43%
|
10.7%
|
8.85%
|
-
|
6.82%
|
6.66%
|
8.26%
|
7.78%
|
Assets
1 |
7,368
|
10,922
|
18,767
|
-
|
23,485
|
24,106
|
26,348
|
28,998
|
Book Value Per Share
2 |
4.350
|
4.960
|
5.670
|
5.790
|
7.030
|
7.790
|
8.840
|
10.00
|
Cash Flow per Share
2 |
0.5300
|
0.9200
|
1.130
|
1.200
|
1.540
|
1.380
|
1.640
|
1.740
|
Capex
1 |
751
|
1,313
|
2,091
|
2,947
|
2,857
|
2,220
|
1,924
|
1,898
|
Capex / Sales
|
19.99%
|
25.57%
|
28.09%
|
28.7%
|
24.76%
|
17.57%
|
12.61%
|
11.64%
|
Announcement Date
|
2/28/20
|
3/28/21
|
3/10/22
|
3/30/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
19.95
CNY Average target price
24.22
CNY Spread / Average Target +21.42% Consensus |
1st Jan change
|
Capi.
|
---|
| -31.16% | 4.29B | | +1.77% | 42.75B | | +47.70% | 41.61B | | +12.24% | 41.34B | | -8.83% | 26.59B | | +7.44% | 25.49B | | -23.01% | 18.12B | | +30.56% | 12.24B | | -1.82% | 11.76B | | +8.35% | 11B |
Other Biotechnology & Medical Research
|